Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Luspatercept Significantly Reduces Red Blood Cell (RBC) Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patients (Pts) with LR-MDS Enrolled in the MEDALIST Trial

Blood (2019) 134 (Supplement_1): 2999.

https://doi.org/10.1182/blood-2019-123655

Published: 2019

Journal Articles

TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes

Elsa Bernard, PhD, Yasuhito Nannya, MD PhD, Tetsuichi Yoshizato, MD PhD, Robert P. Hasserjian, MD, Ryunosuke Saiki, Yusuke Shiozawa, MD PhD, Sean M. Devlin, PhD, Heinz Tuechler, Araxe Sarian, Luca Malcovati, MD, Francesc Sole, PhD, Detlef Haase, MD, Maria Creignou, Max Levine, MS, Ulrich Germing, MD, Catherine Cargo, MB, FRCPath, Yanming Zhang, MD, Juan Medina, MS, Juan E. Arango Ossa, BS, Julie Schanz, MD PhD, Arjan van de Loosdrecht, MD PhD, Martin Jädersten, MD PhD, John M. Bennett, MD, Magnus Tobiasson, MD PhD, Olivier Kosmider, PharmD, PhD, Matilde Y Follo, PhD, Felicitas Thol, MD, Ronald F Pinheiro, MD, Valeria Santini, MD, Ioannis Kotsianidis, Jacqueline Boultwood, Fabio PS Santos, MD, Senji Kasahara, MD PhD, Takayuki Ishikawa, MD PhD, Hisashi Tsurumi, MD PhD, Akifumi Takaori-Kondo, MD PhD, Toru Kiguchi, Chantana Polprasert, MD, Virginia M. Klimek, MD, Michael R. Savona, MD, Monika Belickova, PhD, Christina Ganster, Lionel Ades, MD PhD, Matteo Giovanni Della Porta, MD, Alexandra Smith, PhD, Yesenia Werner, Minal A Patel, MPH, Agnes Viale, PhD, Katelynd Vanness, Donna S Neuberg, ScD, Kristen E. Stevenson, MS, Kamal Menghrajani, MD, Kelly Bolton, MD PhD, Pierre Fenaux, MD PhD, Andrea Pellagatti, Uwe Platzbecker, MD, Michael Heuser, MD, Peter Valent, MD, Shigeru Chiba, MD PhD, Yasushi Miyazaki, MD PhD, Carlo Finelli, Maria Teresa Voso, MD, Lee-Yung Shih, MD, Michaela Fontenay, MD PhD, Joop H. Jansen, PhD, José Cervera, MD PhD, Yoshiko Atsuta, MD PhD, Norbert Gattermann, MD, Benjamin L. Ebert, MD PhD, Rafael Bejar, MD PhD, Peter L Greenberg, MD, Mario Cazzola, MD, Eva Hellstrom Lindberg, MD PhD, Seishi Ogawa, MD PhD, Elli Papaemmanuil, PhD

Blood (2019) 134 (Supplement_1): 675.

https://doi.org/10.1182/blood-2019-129392

Published: 2019

Journal Articles

Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of Oncoproteins

Blood (2019) 134 (Supplement_1): 318.

https://doi.org/10.1182/blood-2019-130549

Published: 2019

Journal Articles

High Burden of Clonal Hematopoiesis in First Responders Exposed to the World Trade Center Disaster

Blood (2019) 134 (Supplement_1): 3720.

https://doi.org/10.1182/blood-2019-129276

Published: 2019

Journal Articles

Deconstructing the Clonal Advantage and Clonal Stability of 5q- Candidate Genes in Del(5q) MDS on a Single Cell Level

Ursula S.A. Stalmann, MD, Fabio Ticconi, MSc, Ronghui Li, MSc, Aaron B. Wong, PhD, Glenn Cowley, PhD, David E. Root, PhD, Dirk Heckl, PhD, Inge Snoeren, MSc, Sergio Martinez, PhDMSc, Tim H Brümmendorf, MD, Andreas Schuppert, PhD, Ivan Costa, PhD, Benjamin L. Ebert, MD PhD, Rebekka K. Schneider, MD PhD

Blood (2019) 134 (Supplement_1): 559.

https://doi.org/10.1182/blood-2019-122588

Published: 2019

Journal Articles

Initial Characterization and Toxicology of an Nmt Inhibitor in Development for Hematologic Malignancies

Michael Weickert, John Dillberger, John R. Mackey, Paul Wyatt, David Gray, Kevin Read, Christian Li, Audrey Parenteau, Luc G. Berthiaume

Blood (2019) 134 (Supplement_1): 3362.

https://doi.org/10.1182/blood-2019-124934

Published: 2019

Journal Articles

Exploiting the Zinc Finger Degrome Targeted By Lenalidomide to Engineer Reversible Off-Switch Degradable Chimeric Antigen Receptors

Max Jan, MD PhD, Ana Castano, MD, Amanda Walker, BA, Andrew A Guirguis, MD PhD, Jessica A Gasser, PhD, Amanda A Bouffard, Mikolaj Slabicki, PhD, Alexander Tepper, Daniel E Grinshpun, Taeyoon Kyung, PhD, Quinlan Sievers, MD PhD, Michael E Birnbaum, PhD, Marcela V Maus, MD PhD, Benjamin L. Ebert, MD PhD

Blood (2019) 134 (Supplement_1): 866.

https://doi.org/10.1182/blood-2019-124210

Published: 2019

Journal Articles

Development of a Pegylated Dimeric Recombinant Factor VIII-Fc Fusion Protein for the Treatment for Hemophilia a Patients

Bin Liu, PhD, Xiaoshan Wang, Master, Xueqin Li, Master, Haixia Yan, PhD, Shuya Wang, Master, Xi Zhu, Pengju Wang, Jie Gao, Master, Yali Wang, PhD, Hongsheng Su, PhD

Blood (2018) 132 (Supplement 1): 3783.

https://doi.org/10.1182/blood-2018-99-112030

Published: 2018

Journal Articles

Clinical Translation of Pluripotent Cell-Derived Off-the-Shelf Natural Killer Cell Cancer Immunotherapy

Blood (2017) 130 (Supplement 1): 656.

https://doi.org/10.1182/blood.V130.Suppl_1.656.656

Published: 2017

Journal Articles

Engineered Antigen-Specific Human Regulatory T Cells Suppress Both FVIII-Specific T- and B-Cell Responses

Yong Chan Kim, PhD, Aihong Zhang, PhD, Kathleen P. Pratt, PhD, Ethan Shevach, MD, David William Scott, PhD

Blood (2014) 124 (21): 239.

https://doi.org/10.1182/blood.V124.21.239.239

Published: 2014

Journal Articles

Rofecoxib Does Not Appear to Increase the Risk of Venous Thromboembolism: A Systematic Review of the Literature,

Jennifer K Goy, MD, Jeremy Paikin, MD, Mark A. Crowther, MD

Blood (2011) 118 (21): 3334.

https://doi.org/10.1182/blood.V118.21.3334.3334

Published: 2011

Journal Articles

Population-Based Analysis of Late Cardiovascular Morbidity and Hospitalizations After Hematopoietic Cell Transplantation.

Eric J Chow, MD, MPH, K. Scott Baker, MD, MS, Debra L. Friedman, MD, MS, Kara Cushing-Haugen, MS, Mary E.D. Flowers, MD, Beth A Mueller, DrPH, Stephanie J. Lee, MD, MPH

Blood (2009) 114 (22): 517.

https://doi.org/10.1182/blood.V114.22.517.517

Published: 2009

Journal Articles

“Getting to go” for FDA Approvals for the Treatment of Hematologic Versus Solid Tumor Malignancies: A Report from the Research on Adverse Drug Events and Reports (RADAR) Project

Elizabeth A Richey, BA, Veena Shankaran, MD, Steven Hirschfeld, MD, PhD, Steven M Trifilio, RPh, June McKoy, MD, MPH, Kenneth R Carson, MD, Beatrice J Edwards, MD, FACP, Thanh Ha Luu, BA, Narissa Nonzee, BS, A. Oliver Sartor, MD, Charles L. Bennett, MD, PhD, MPP

Blood (2008) 112 (11): 2402.

https://doi.org/10.1182/blood.V112.11.2402.2402

Published: 2008

Journal Articles

Inhibition of Multiple Myeloma Tumor Growth and FGFR3 by the Aurora-Angiogenesis Inhibitor ENMD-981693.

Todd A. Hembrough, Xiaoru Chen, Patricia A. Burke, Glenn M. Swartz, Kathleen Bengali, Richard Brokx, Theresa M. LaVallee, Mark R. Bray

Blood (2007) 110 (11): 1209.

https://doi.org/10.1182/blood.V110.11.1209.1209

Published: 2007

Journal Articles

Economic Impact of Adverse Events in Chronic Myelogenous Leukemia: A Cost of Treatment Analysis of Dasatinib.

Sarah Y. Liou, Kimbach T. Tran, MPH, MS, Jennifer M. Stephens, PharmD, Nneka C. Onwudiwe, PharmD, Marc F. Botteman, MSc, MA

Blood (2006) 108 (11): 3309.

https://doi.org/10.1182/blood.V108.11.3309.3309

Published: 2006

NARROW

Luspatercept Significantly Reduces Red Blood Cell (RBC) Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patients (Pts) with LR-MDS Enrolled in the MEDALIST Trial

TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes

Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of Oncoproteins

High Burden of Clonal Hematopoiesis in First Responders Exposed to the World Trade Center Disaster

Deconstructing the Clonal Advantage and Clonal Stability of 5q- Candidate Genes in Del(5q) MDS on a Single Cell Level

Initial Characterization and Toxicology of an Nmt Inhibitor in Development for Hematologic Malignancies

Exploiting the Zinc Finger Degrome Targeted By Lenalidomide to Engineer Reversible Off-Switch Degradable Chimeric Antigen Receptors

Development of a Pegylated Dimeric Recombinant Factor VIII-Fc Fusion Protein for the Treatment for Hemophilia a Patients

Clinical Translation of Pluripotent Cell-Derived Off-the-Shelf Natural Killer Cell Cancer Immunotherapy

Engineered Antigen-Specific Human Regulatory T Cells Suppress Both FVIII-Specific T- and B-Cell Responses

Rofecoxib Does Not Appear to Increase the Risk of Venous Thromboembolism: A Systematic Review of the Literature,

Population-Based Analysis of Late Cardiovascular Morbidity and Hospitalizations After Hematopoietic Cell Transplantation.

“Getting to go” for FDA Approvals for the Treatment of Hematologic Versus Solid Tumor Malignancies: A Report from the Research on Adverse Drug Events and Reports (RADAR) Project

Inhibition of Multiple Myeloma Tumor Growth and FGFR3 by the Aurora-Angiogenesis Inhibitor ENMD-981693.

Economic Impact of Adverse Events in Chronic Myelogenous Leukemia: A Cost of Treatment Analysis of Dasatinib.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only